Testing binimetinib for BRAF fusion brain tumors and pancreatic cancer
Treatments studied
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This trial tests a targeted drug, binimetinib, for people with low-grade glioma (a type of brain tumor) or pancreatic cancer that has a specific genetic change called a BRAF fusion. The drug aims to block signals that help these tumors grow.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a low-grade glioma (brain tumor) that is slow-growing or pancreatic cancer that has spread or cannot be removed by surgery.
- A genetic test shows you have a BRAF fusion or rearrangement in your tumor.
- You are at least 12 years old and weigh at least 40 kg (about 88 pounds) for the brain tumor group, or at least 18 for the pancreatic cancer group.
- You have not had chemotherapy in the last 14 days, or other targeted or immune therapy in the last 21 days.
- Your heart, liver, kidney, and blood cell counts are within certain safe ranges (checked by blood tests and an echocardiogram).
- You are willing to use effective contraception during and for a time after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two targeted drugs (dabrafenib and trametinib) for children and young adults with a specific type of low-grade brain tumor that has a BRAF V600 mutation. The drugs work by blocking signals that help the tumor grow.
This trial tests a combination of targeted therapy (dabrafenib and trametinib) and immunotherapy (nivolumab) for children and young adults with certain BRAF gene changes in their glioma. It aims to see if this drug combination can shrink tumors or stop them from growing.
This trial tests a new targeted medicine (FCN-159) against standard chemotherapy for children with slow-growing brain or nervous system tumors that have a specific genetic change (BRAF alteration). The goal is to see if the new pill works better at shrinking or controlling the tumor.
This trial tests three new targeted drug combinations for pancreatic cancer that has a specific genetic change (KRAS G12D). They are comparing the study drug alone versus combining it with other investigational drugs to see which works better.
This trial tests a drug called Belvarafenib for people with brain tumors that have a BRAF gene change (mutation). The drug targets this specific change to try to shrink or control the tumor. It is for patients whose brain tumor has come back or hasn't responded to other treatments.
This Phase 2 study tests whether a 3-drug plan (encorafenib + binimetinib + nivolumab) works better than ipilimumab + nivolumab for melanoma that has spread to the brain. If you qualify, you’ll get either treatment and have frequent brain scans to track how well it controls the tumors.
Hear when a new Low-grade Glioma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.